Annual report
4572.TEDINET S100XSFK
Period2025-01-01 → 2025-12-31
Filed2026-03-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 133
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥579m | 2025-01-01 → 2025-12-31 | Cons. | Net sales |
| Revenue | ¥636m | 2024-01-01 → 2024-12-31 | Cons. | Net sales |
| Revenue | ¥1.6bn | 2023-01-01 → 2023-12-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.4bn | 2022-01-01 → 2022-12-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.0bn | 2021-01-01 → 2021-12-31d | Cons. | Net sales (5-year summary) |
| Operating income | −¥2.1bn | 2025-01-01 → 2025-12-31 | Cons. | Operating income |
| Operating income | −¥2.1bn | 2024-01-01 → 2024-12-31 | Cons. | Operating income |
| Ordinary income | −¥2.1bn | 2025-01-01 → 2025-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥2.1bn | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2023-01-01 → 2023-12-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.3bn | 2022-01-01 → 2022-12-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥523m | 2021-01-01 → 2021-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥2.2bn | 2025-01-01 → 2025-12-31 | Cons. | Income before income taxes |
| Profit before tax | −¥2.2bn | 2024-01-01 → 2024-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥2.2bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.2bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.2bn | 2023-01-01 → 2023-12-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.3bn | 2022-01-01 → 2022-12-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥534m | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥2.2bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss |
| Net income | −¥2.2bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss |
| Total assets | ¥1.2bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥2.8bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥4.3bn | at 2023-12-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥4.3bn | at 2022-12-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥5.4bn | at 2021-12-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥920m | at 2025-12-31 | Cons. | Liabilities |
| Total liabilities | ¥297m | at 2024-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥309m | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥2.5bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥3.9bn | at 2023-12-31v | Cons. | Net assets |
| Net assets / equity | ¥3.6bn | at 2022-12-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥4.3bn | at 2021-12-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥517m | at 2025-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.1bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥517m | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2023-12-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.4bn | at 2022-12-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥3.8bn | at 2021-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥2.2bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.4bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.7bn | 2023-01-01 → 2023-12-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥708m | 2022-01-01 → 2022-12-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.5bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥25m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11m | 2023-01-01 → 2023-12-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥126m | 2022-01-01 → 2022-12-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥42m | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥605m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥567m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.2bn | 2023-01-01 → 2023-12-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥367m | 2022-01-01 → 2022-12-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-113.62 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-121.64 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-68.62 | 2023-01-01 → 2023-12-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-99.1 | 2022-01-01 → 2022-12-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-42.1 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥16.16 | at 2025-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥129.62 | at 2024-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥226.16 | at 2023-12-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥255.04 | at 2022-12-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥323.54 | at 2021-12-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 25.1% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.3% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.1% | at 2023-12-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.0% | at 2022-12-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.3% | at 2021-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Employees | 61 | at 2025-12-31 | Cons. | Number of employees |
| Employees | 63 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 67 | at 2023-12-31v | Cons. | Number of employees |
| Employees | 65 | at 2022-12-31v | Cons. | Number of employees |
| Employees | 64 | at 2021-12-31d | Cons. | Number of employees |
| Revenue | ¥491m | 2025-01-01 → 2025-12-31 | Standalone | Net sales |
| Revenue | ¥542m | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥1.5bn | 2023-01-01 → 2023-12-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.2bn | 2022-01-01 → 2022-12-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.9bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥2.0bn | 2025-01-01 → 2025-12-31 | Standalone | Operating income |
| Operating income | −¥2.1bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Ordinary income | −¥2.1bn | 2025-01-01 → 2025-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥2.1bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.2bn | 2023-01-01 → 2023-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.4bn | 2022-01-01 → 2022-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥549m | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥2.1bn | 2025-01-01 → 2025-12-31 | Standalone | Income before income taxes |
| Profit before tax | −¥2.2bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Net income | −¥2.1bn | 2025-01-01 → 2025-12-31 | Standalone | Profit loss |
| Net income | −¥2.2bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | −¥1.2bn | 2023-01-01 → 2023-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.4bn | 2022-01-01 → 2022-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥556m | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.1bn | at 2025-12-31 | Standalone | Assets |
| Total assets | ¥2.5bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥4.1bn | at 2023-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.0bn | at 2022-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥5.3bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.1bn | at 2025-12-31 | Standalone | Liabilities |
| Total liabilities | ¥294m | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥66m | at 2025-12-31 | Standalone | Net assets |
| Net assets / equity | ¥2.2bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥3.6bn | at 2023-12-31v | Standalone | Net assets |
| Net assets / equity | ¥3.4bn | at 2022-12-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.2bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥413m | at 2025-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2024-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-112.09 | 2025-01-01 → 2025-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-121.08 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-70.53 | 2023-01-01 → 2023-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-103.2 | 2022-01-01 → 2022-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-43.83 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥3.45 | at 2025-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥115.11 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥211.43 | at 2023-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥240.82 | at 2022-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥314.45 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 5.8% | at 2025-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.2% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.7% | at 2023-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.6% | at 2022-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.9% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 19,150,500 | at 2025-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 19,107,500 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,151,900 | at 2023-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 14,218,300 | at 2022-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 13,313,400 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 57 | at 2025-12-31 | Standalone | Number of employees |
| Employees | 60 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 64 | at 2023-12-31v | Standalone | Number of employees |
| Employees | 62 | at 2022-12-31v | Standalone | Number of employees |
| Employees | 61 | at 2021-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 35
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment assets | at 2025-12-31 | ¥528m |
| Drug Discovery Businessreportable segment | capex | 2025-01-01 → 2025-12-31 | ¥18m |
| Drug Discovery Businessreportable segment | employees | at 2025-12-31 | 33 pure |
| Drug Discovery Businessreportable segment | segment assets | at 2025-12-31 | ¥313m |
| Drug Discovery Businessreportable segment | segment profit | 2025-01-01 → 2025-12-31 | −¥2.0bn |
| Drug Discovery Support Businessreportable segment | capex | 2025-01-01 → 2025-12-31 | ¥7m |
| Drug Discovery Support Businessreportable segment | employees | at 2025-12-31 | 20 pure |
| Drug Discovery Support Businessreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥579m |
| Drug Discovery Support Businessreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥579m |
| Drug Discovery Support Businessreportable segment | segment assets | at 2025-12-31 | ¥388m |
| Drug Discovery Support Businessreportable segment | segment profit | 2025-01-01 → 2025-12-31 | −¥51m |
| —segment total | capex | 2025-01-01 → 2025-12-31 | ¥25m |
| —segment total | revenue | 2025-01-01 → 2025-12-31 | ¥579m |
| —segment total | revenue external | 2025-01-01 → 2025-12-31 | ¥579m |
| —segment total | segment assets | at 2025-12-31 | ¥701m |
| —segment total | segment profit | 2025-01-01 → 2025-12-31 | −¥2.1bn |
| Reconciling Itemsreconciling | segment assets | at 2024-12-31 | ¥1.9bn |
| Drug Discovery Businessreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥9m |
| Drug Discovery Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥8m |
| Drug Discovery Businessreportable segment | segment assets | at 2024-12-31 | ¥291m |
| Drug Discovery Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥2.0bn |
| Drug Discovery Support Businessreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥9m |
| Drug Discovery Support Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥23m |
| Drug Discovery Support Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥636m |
| Drug Discovery Support Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥636m |
| Drug Discovery Support Businessreportable segment | segment assets | at 2024-12-31 | ¥566m |
| Drug Discovery Support Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥34m |
| —segment total | capex | 2024-01-01 → 2024-12-31 | ¥18m |
| —segment total | depreciation | 2024-01-01 → 2024-12-31 | ¥31m |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥636m |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥636m |
| —segment total | segment assets | at 2024-12-31 | ¥857m |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | −¥2.1bn |
| Drug Discovery Businessreportable segment | employees | at 2025-12-31 | 32 pure |
| Drug Discovery Support Businessreportable segment | employees | at 2025-12-31 | 17 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,288
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 8 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 8 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 10 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 13 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 0.9092 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.4290 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.4307 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.2475 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.2937 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.1274 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.0998 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.4105 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.6991 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.1316 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | 33 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | 5 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 20 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 6 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 8 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 2 | |
| Number of employees | CurrentYearInstant | 61 | |
| Average number of temporary workers | CurrentYearInstant | 13 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 57 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 13 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 47.6 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 11.6 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 7919000 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | 32 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | 5 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 17 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 6 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 8 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 2 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 57 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 13 | |
| Research and development expenses research and development activities | CurrentYearDuration | 1851353000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | 1766529000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 84824000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 10233000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 1208000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | 7681000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 19150500 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 19196700 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 19150500 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 19196700 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 4 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 19 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 64 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |